Cardiovascular Drug Access in Australia and New Zealand: New PBS and PHARMAC Listings, 2023-2025.
A policy review identified five newly PBS-listed cardiovascular drugs (inclisiran, mavacamten, tafamidis, icosapent ethyl, migalastat) and two new cardiometabolic indications for SGLT2 inhibitors (empagliflozin and dapagliflozin for HFpEF) in Australia and New Zealand during 2023-2025. These changes reflect meaningful expansion of subsidized access to evidence-based cardiovascular therapies across both healthcare systems.
A policy review identified five newly PBS-listed cardiovascular drugs (inclisiran, mavacamten, tafamidis, icosapent ethyl, migalastat) and two new cardiometabolic indications for SGLT2 inhibitors (empagliflozin and dapagliflozin for HFpEF) in Australia and New Zealand during 2023-2025. These changes reflect meaningful expansion of subsidized access to evidence-based cardiovascular therapies across both healthcare systems.
What the study was
- Study design
- Review
- Category
- Prevention
- Maturity
- Exploratory
- Journal
- Heart, lung & circulation
Why it surfaced
Relevant Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk study (novel treatment potential) meets standard-priority threshold.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.